Jasper Therapeutics, Inc. (JSPR)
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies.
It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.
The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts.
The company is headquartered in Redwood City, California.
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 45 |
CEO | Ronald A. Martell |
Contact Details
Address: 2200 Bridge Pkwy Suite #102 Redwood City, California 94065 United States | |
Phone | (650) 549-1400 |
Website | jaspertherapeutics.com |
Stock Details
Ticker Symbol | JSPR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001788028 |
CUSIP Number | 471871103 |
ISIN Number | US4718712023 |
Employer ID | 84-2984849 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Ronald A. Martell | President, Chief Executive Officer and Director |
Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Chair of Scientific Advisory Board and Director |
Jeetinder Singh Mahal M.B.A. | Chief Operating Officer |
Herbert C. Cross | Chief Financial Officer and Corporate Secretary |
Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
David Ku M.D. | Vice President of Corporate Development, Portfolio Strategy and Management |
Matthew Ford | Vice President of Human Resources |
Dr. Wendy Pang M.D., Ph.D. | Senior Vice President of Research and Translational Medicine |
Dr. Edwin Jonathan Tucker M.D. | Chief Medical Officer |
Patricia Carlos | Senior Vice President of Regulatory Affairs and Quality |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 12, 2024 | 144 | Filing |
Mar 6, 2024 | 144 | Filing |
Mar 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 5, 2024 | 10-K | Annual Report |
Mar 4, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |